In oncology, the educational challenge is rarely a lack of information. The greater problem is timing: new biomarkers, indications, combination regimens and treatment sequences can alter clinical questions faster than a conventional education plan can be updated. For pharmaceutical and biotech teams, oncology medical education therefore has to remain aligned with a treatment landscape that may change while a programme is still being developed.

That creates a practical risk. Education can be scientifically accurate yet still arrive too late, focus on evidence that no longer represents the main clinical uncertainty or overlook the point in the care pathway where understanding is most needed. The result is activity without enough educational relevance.

For companies looking to rank medical education companies for oncology programs, the key issue is not simply who can produce content. It is who can identify the oncology-specific educational gap, interpret new evidence in context and turn that insight into a programme that remains useful as practice evolves.

This article explains what pharmaceutical companies should prioritise, which oncology-specific capabilities matter when evaluating a partner and how Billev Pharma East can support programmes from educational direction through execution. Our Medical education services help companies translate complex scientific developments into structured, clinically relevant education designed around the needs of healthcare professionals.

What should pharmaceutical companies do before developing oncology medical education?

Pharmaceutical companies should build oncology medical education around the clinical questions created by a changing treatment landscape, rather than around individual assets or isolated sets of data.

The first step is to identify where new evidence is likely to create uncertainty in clinical practice. In oncology, this may happen when a new biomarker changes patient selection, when a treatment moves into an earlier line, when a new combination alters sequencing decisions or when emerging safety data affect how a therapy is managed. The educational priority should therefore come from the gap between new evidence and the decisions healthcare professionals need to make.

A structured medical education consulting approach can help companies translate those identified gaps into clear educational objectives and determine how the programme should respond to changing scientific and clinical needs.

Companies should then define the audience and the clinical context in which that knowledge will be used. Oncology care is inherently multidisciplinary, so education aimed at oncologists may require a different emphasis from education developed for pathologists, pharmacists, nurses or other members of the cancer care team.

The programme should also be designed to evolve. Oncology evidence can change rapidly, so educational priorities, content and learning objectives should be reviewed as new studies, indications, biomarkers or treatment approaches emerge.

The strongest programmes therefore start with a clear clinical need, translate that need into a focused educational objective and maintain enough flexibility to remain relevant as oncology practice develops.

How does Billev Pharma East strengthen oncology medical education programmes?

Billev Pharma East helps pharmaceutical and biotech companies decide what their oncology education should focus on before resources are committed to content development.

In oncology, the challenge is often not access to scientific data, but determining which developments are important enough to change what healthcare professionals need to understand. A new biomarker, indication, combination strategy or treatment sequence can create a very different educational need from one market or stage of the product lifecycle to another. Without that prioritisation, companies risk developing programmes that are scientifically accurate but no longer address the most relevant clinical questions.

Our role is to bring that focus to oncology medical education. Billev Pharma East can work with Medical Affairs teams to interpret the scientific and clinical context, identify where education is most needed and define a programme around those priorities. When additional external expertise or capacity is required, a focused medical education service can help translate those priorities into scientifically robust educational activities without creating unnecessary complexity for the internal team.

Because our expertise extends across Medical Affairs, medical writing, pharmacovigilance and regulatory affairs, we can also consider the broader scientific and compliance context surrounding the programme rather than treating education as an isolated activity.

This allows companies to move from a growing volume of oncology evidence to a clearer educational direction: what needs to be communicated, to whom, why it matters and how the programme should evolve as the evidence changes.

What should companies consider when ranking medical education partners for oncology programs?

When companies rank medical education companies for oncology programs, the assessment should focus on capabilities that are specific to oncology rather than on the size of a provider’s service catalogue.

The first question is whether the partner can interpret new evidence within the broader treatment landscape. A new study may affect patient selection, sequencing, biomarker testing, safety management or the role of a therapy in a particular line of treatment. A partner should be able to recognise which of those changes creates an educational priority and which information is supporting context rather than the centre of the programme.

The second question is whether the provider can connect the scientific objective with the audience and clinical setting. The strongest oncology medical education is not a single scientific narrative reproduced for every stakeholder. It reflects how different healthcare professionals encounter the evidence and where they contribute to the treatment pathway.

Companies should also assess whether the provider can adapt the programme as the evidence changes and whether success can be evaluated against the original learning objective. These criteria provide a more useful basis for comparing oncology education partners than deliverable volume alone.

Why should oncology medical education reflect multidisciplinary cancer care?

Oncology medical education should reflect the fact that modern cancer care is rarely delivered by one specialty. Treatment decisions may involve medical oncologists, surgeons, radiation oncologists, pathologists, radiologists, pharmacists, nurses and other specialists, each contributing different information to diagnosis, treatment selection and ongoing management.

This matters because an educational programme that starts and ends with the medicine can miss important decision points elsewhere in the care pathway. Biomarker testing, pathology, imaging, treatment sequencing and toxicity management may all influence the same patient’s treatment, but they are interpreted by different members of the cancer care team.

The ESMO/ASCO Global Curriculum reflects this multidisciplinary reality and is updated as oncology practice develops. For pharmaceutical companies, the implication is clear: educational planning should consider where each relevant professional interacts with the evidence and what that person needs to understand to support the intended clinical decision.

A strong programme therefore does not simply distribute the same scientific content to multiple audiences. It connects one educational strategy with the distinct roles that healthcare professionals play across the oncology pathway.

How should oncology medical education address biomarker-driven treatment decisions?

Biomarkers increasingly influence patient classification, treatment eligibility and the interpretation of clinical evidence. As a result, oncology medical education may need to explain not only the therapy, but also the diagnostic and molecular context that determines where the evidence applies.

The educational objective should reflect the full decision pathway. Healthcare professionals may need to understand when testing is relevant, which population was studied, how results should be interpreted and how biomarker status interacts with other clinical factors. ASCO guidelines are developed around specific clinical situations and can include the use of tests as well as treatments, illustrating how closely diagnostics and treatment decisions can be connected in oncology.

This becomes particularly important when testing pathways are complex or when several molecular and clinical variables influence a treatment choice. In such cases, presenting a biomarker as an isolated scientific fact can leave the most important educational question unanswered: how should the result influence the next clinical decision?

For pharmaceutical companies, biomarker education should therefore be planned around the point at which testing, evidence and treatment selection meet. That makes the programme more relevant to real oncology practice and strengthens the connection between scientific information and clinical reasoning.

How should companies measure the impact of oncology medical education?

Effective oncology medical education should be designed with a clear definition of success before the programme begins. Attendance, completion rates and satisfaction can show reach and participant experience, but they do not establish whether the education changed understanding, competence or practice.

The appropriate outcome should follow directly from the educational gap. A programme may aim to improve interpretation of a new biomarker, strengthen competence around treatment sequencing or support the application of emerging evidence in practice. ACCME’s educational planning framework similarly links education to identified professional practice gaps and distinguishes changes in competence, performance and patient outcomes.

For oncology programmes, evaluation is also useful because the evidence base continues to move. Results can show where uncertainty remains, whether the original learning objective was achieved and whether a new educational priority has emerged as guidelines or treatment options change.

Measurement should therefore be planned at the same time as the educational strategy. When the clinical gap, learning objective, content and evaluation method are aligned from the start, companies have a stronger basis for refining the programme and deciding what education should come next.

Why choose Billev Pharma East for oncology medical education?

Strong oncology medical education requires more than accurate content. It depends on identifying the right educational priorities, understanding how new evidence may affect clinical practice and designing programmes that remain relevant as the oncology landscape evolves.

For pharmaceutical and biotech companies, the choice of partner is therefore critical. A provider should be able to connect scientific interpretation, educational strategy and practical execution rather than treat medical education as a standalone content task. Access to an experienced medical education specialist can be particularly valuable when a programme requires deeper scientific interpretation or additional expertise that is not available within the internal Medical Affairs team.

Billev Pharma East supports companies with multidisciplinary Medical Affairs expertise that can be combined with medical writing, pharmacovigilance and regulatory knowledge when needed. This broader scientific support model allows educational programmes to be developed in the context of the evidence, the therapeutic area and the wider requirements surrounding pharmaceutical communication.

If your organisation is evaluating providers to rank medical education companies for oncology programs, Billev Pharma East can help you move from a complex oncology evidence landscape to a focused, clinically relevant educational programme designed around your objectives.

Frequently asked questions about oncology medical education

Sources: 1 – American Society of Clinical Oncology (ASCO). ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology, 2 – American Society of Clinical Oncology (ASCO). Global Courses, 3 – American Society of Clinical Oncology (ASCO). Clinical Practice Guidelines, 4 – Accreditation Council for Continuing Medical Education (ACCME). Educational Needs, 5 – Accreditation Council for Continuing Medical Education (ACCME). Accreditation Criteria, 6 – Multidisciplinary Oncology Education Among Postgraduate Trainees: Systematic Review. PubMed.